BioNTech Halts Phase II Autogene Cevumeran Trial in Colorectal Cancer

Companies: BioNTech / Genentech · Asset: Autogene Cevumeran (BNT122) · Trial: BNT122-01 (Phase II) · Indication: Colorectal Cancer · Date: August 27, 2026 Summary BioNTech terminated the Phase II BNT122-01 trial of its individualized neoantigen mRNA cancer vaccine autogene cevumeran in colorectal cancer after an…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Ipsen Acquires Kartos Therapeutics for Up to $1.75B
Kuva Merger Collapse Forces Lisata Therapeutics Retrenchment
Gilead – $5B Tubulis Acquisition
Scribe Sets Terms for a $100 Million IPO